Partnership

Careers

Contact Us

Empowering the Fight for
Health and Well-being as
a
Human Right

Our Success in
Numbers

Our Success in Numbers

Pioneering Healthcare Solutions Globally

At Citadel Pharma, we are committed to continuously innovate, striving to discover solutions that enhance the quality of life for everyone, both today and tomorrow.

Fulfilling unmet patient needs

We tailor our healthcare solutions in response to the most demanding unmet medical needs. Our therapeutic areas of focus include oncology, neuroscience, respiratory, cardiometabolic medicine, anti-infectives, ophthalmology, bone health and pain management, hepatology, slimming and wellbeing, sexual and reproductive health.

Bridging the globe through the catalytic power of partnerships

We believe in the sustainable impact of collaborations. With a track record of successful alliances, we play a crucial role in delivering life-saving treatments for pressing health challenges such as HIV, HBV, HCV, COVID-19 and diabetes. And today we are pioneering the tech. transfer and local manufacturing of diverse biological treatments for sustainable accessibility in low- to middle-income countries.

Innovating for a better quality of life

With a heritage that spans a century, we have in-house expertise that power both manufacturing and research capabilities. Our three, globally certified, manufacturing facilities are supported with 2 research centers that ensure we not only create cutting-edge and innovative solutions, but also have the scale to produce them to the mass.

Research and development is at the heart of everything we do.

We know that investing in innovation is investing in our future.

Happening at Citadel Pharma

Highlights

News and Media
Citadel Pharma and BeiGene Announce a Strategic Partnership to Bring Innovative Oncology Therapies to Patients in Egypt
27 Mar, 2025
News and Media
Lilly and Citaldel Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
27 Mar, 2025
News and Media
Citadel Pharma Signs a Voluntary Licensing Agreement with Gilead to Increase Access to Lenacapavir in 120 Countries with High HIV Incidence and Limited Resources
27 Mar, 2025